Bayer, Aignostics to collaborate on next generation precision oncology
Berlin: Bayer and Aignostics GmbH have announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin. The partners will co-create a novel target identification platform that leverages Aignostics’ technology and proprietary multimodal patient cohorts, […]